243 related articles for article (PubMed ID: 26419361)
1. Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Hamner JB; White M; Crowder C; Singh G
World J Surg Oncol; 2015 Sep; 13():290. PubMed ID: 26419361
[TBL] [Abstract][Full Text] [Related]
2. Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report.
Frei L; Stieger R; Bayerl C; Breitenstein S; Staerkle RF
J Med Case Rep; 2017 Jul; 11(1):194. PubMed ID: 28716115
[TBL] [Abstract][Full Text] [Related]
3. Metachronous multiple adenocarcinomas of the pancreas.
Ikematsu Y; Tamura H; Nakata Y; Hayashi T; Kanai T; Hirayama K; Mori H; Ozawa T; Hasegawa S; Okawada T; Kageyama S; Sugimura H; Nishiwaki Y
Int J Clin Oncol; 2011 Dec; 16(6):726-31. PubMed ID: 21365362
[TBL] [Abstract][Full Text] [Related]
4. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
6. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
8. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
Lovecek M; Skalicky P; Chudacek J; Szkorupa M; Svebisova H; Lemstrova R; Ehrmann J; Melichar B; Yogeswara T; Klos D; Vrba R; Havlik R; Mohelnikova-Duchonova B
World J Gastroenterol; 2017 Sep; 23(35):6420-6428. PubMed ID: 29085191
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy.
Dalla Valle R; Mancini C; Crafa P; Passalacqua R
JOP; 2006 Sep; 7(5):473-7. PubMed ID: 16998244
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
[TBL] [Abstract][Full Text] [Related]
11. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
13. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ
Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
[TBL] [Abstract][Full Text] [Related]
17. [Re-resection for local recurrence in the remnant pancreas after pancreaticoduodenectomy for pancreatic cancer- a case report].
Kim C; Tono T; Kimura Y; Watanabe A; Nakamura H; Inadome J; Danno K; Kagara N; Taniguchi H; Kanoh T; Ohnishi T; Nakano Y; Monden T; Imaoka S
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2448-50. PubMed ID: 22202409
[TBL] [Abstract][Full Text] [Related]
18. Metastatic pulmonary adenocarcinoma 6 years after curative resection for ampullary adenocarcinoma. Metastatic disease from initial primary or metachronous tumour?
Giakoustidis A; Cherian PT; Zen Y; Jassem W; Prachalias A; Srinivasan P; Heaton ND; Rela M
JOP; 2011 Jan; 12(1):32-6. PubMed ID: 21206098
[TBL] [Abstract][Full Text] [Related]
19. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
